Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Research and Markets has announced the addition of the "Oncology Review and Outlook 2010" report to their offering.

Cancer is the second-leading cause of death in the United States. The opportunity to improve upon current oncology treatments is significant as these medications are, on average, only 25% effective in the advanced disease setting. The urgent need for effective cancer diagnostics and treatments is forecasted to increase as the population ages. Presently, more than 800 drugs are under investigation for cancer.

The amount of oncology drugs in the overall pharma/biotech product pipeline is more than twice the number of any other therapeutic area. Company developers as well as clinicians are searching for better approaches to target tumors. For instance, a new generation of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become blockbuster brands.

This special report focuses on the market leaders for oncology as well as the products in development anticipated to head this therapeutic area in the years to come. This compilations prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of oncology prescription-drug developers and marketers is included.

Additionally provided in this report is a listing of oncology medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the cancer field.

Source: Research and Markets